Table 2.
Cox proportional hazards analyses of the association between PFS and the predicted level of resistance to the considered drugs in the merged IDRC and LLMPP cohort
| Univariate (N = 690) | Multivariate (N = 604) | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| REGS classifier | ||||
| CHO | 2.33 (1.64,3.30) | 2.05e-06 | 2.30 (1.57,3.37) | 1.78e-05 |
| Cyclophosphamide (C) | 0.95 (0.70,1.30) | 0.764 | 0.99 (0.71,1.37) | 0.949 |
| Doxorubicin (H) | 2.52 (1.77,3.59) | 2.81e-07 | 2.55 (1.74,3.72) | 1.29e-06 |
| Vincristine (O) | 2.07 (1.48,2.88) | 2.04e-05 | 1.69 (1.19,2.40) | 0.003 |
| REGS predictor | ||||
| CHO | 1.22 (1.09,1.36) | 0.000353 | 1.22 (1.09,1.37) | 0.0009 |
| Cyclophosphamide (C) | 0.97 (0.92,1.02) | 0.184 | 0.98 (0.93,1.03) | 0.438 |
| Doxorubicin (H) | 1.10 (1.05,1.16) | 5.53e-05 | 1.10 (1.04,1.16) | 0.0005 |
| Vincristine (O) | 1.67 (1.38,2.01) | 9.3e-08 | 1.59 (1.30,1.93) | 4.79e-06 |
In the multivariate analysis the Cox proportional hazards regression is adjusted for IPI. The estimated HR’s for the REGS classifiers compare patients classified as resistant to patients classified as sensitive. In contrast, the estimated HR’s for the REGS predictors are based on an increase of 10 in the predicted AUC0.